Stuart Davis
Psychiatry · Peachtree City, GANPI 1811043540
Payments from drug & device makers
Across 729 payments — averaging $158.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$53K
- Ironshore Pharmaceuticals Inc.$40K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- Neuronetics, Inc.$2K
- Supernus Pharmaceuticals, Inc.$1K
- Lundbeck LLC$1K
- plus $5K from 25 others
What the payments were for
- Speaking & faculty fees$90,75879%
- Travel & lodging$10,1769%
- Food & beverage$14,06212%
- Education$2720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 153 | $53,105 |
| Ironshore Pharmaceuticals Inc. | 88 | $39,656 |
| Takeda Pharmaceuticals U.S.A., Inc. | 95 | $12,811 |
| Neuronetics, Inc. | 6 | $1,958 |
| Supernus Pharmaceuticals, Inc. | 28 | $1,151 |
| Lundbeck LLC | 57 | $1,139 |
| Teva Pharmaceuticals USA, Inc. | 30 | $741 |
| Otsuka America Pharmaceutical, Inc. | 42 | $683 |
| Alkermes, Inc. | 33 | $681 |
| Axsome Therapeutics, Inc. | 24 | $574 |
| Bausch Health US, LLC | 46 | $458 |
| Tris Pharma Inc | 20 | $397 |
| Corium, LLC | 21 | $366 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $281 |
| Neos Therapeutics, LP | 13 | $236 |
| Avanir Pharmaceuticals, Inc. | 14 | $235 |
| Noven Therapeutics, LLC | 9 | $176 |
| Sunovion Pharmaceuticals Inc. | 6 | $105 |
| Johnson & Johnson | 5 | $91 |
| Vanda Pharmaceuticals Inc. | 6 | $91 |
| Idorsia Pharmaceuticals US Inc | 5 | $90 |
| Eisai Inc. | 4 | $49 |
| Adlon Therapeutics L.p. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $25 |
| Aytu Biopharma, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Merck | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$51,129
- Jornay PM 20mg capsules (Bottle of 100)$30,577
- VYVANSE$11,462
- JORNAY PM$7,900
- NEUROSTAR TMS THERAPY SYSTEM$1,878
- LYBALVI$402
- VIIBRYD$200
- AUSTEDO$125
- CAPLYTA$107
- Auvelity$102
How this compares
$115,268 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 24 | $43,249 |
| Lisdexamfetamine Dimesylate | 38 | $8,411 |
| Aripiprazole | 24 | $6,927 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,636 |
| BelsomraSuvorexant | 11 | $4,960 |
| Bupropion XlBupropion Hcl | 92 | $3,100 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 76 | $2,425 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $1,218 |
| Olanzapine OdtOlanzapine | 11 | $1,161 |
| Eszopiclone | 34 | $1,069 |
| Clonazepam | 152 | $967 |
| Trazodone Hcl | 54 | $896 |
| Escitalopram Oxalate | 51 | $884 |
| Quetiapine Fumarate | 37 | $563 |
| Fluoxetine Hcl | 45 | $532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $683 | $43,24924 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $12,811 | $6,63616 claims |
| MerckBelsomra | $16 | $4,96011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Peachtree City
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Michael MobleySavannah$2.9M
- Richard PettyLoganville$2.9M
- Felipe SuplicyRome$2.3M
- Angelo SambunarisAlpharetta$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.